Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...
(Image Credits: Pixabay) The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and ...
SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...
SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of ...
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement ... “Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin ...
Earlier this month, non-profit drugmaker Civica Rx pledged to launch biosimilars of three big-selling insulin products in the US – Sanofi's Lantus, Novo Nordisk's Novolog and Eli Lilly's Humalog ...